Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Rachel A Eiring"'
Autor:
Jennifer J. Gile, Patrick W. McGarrah, Konstantinos Leventakos, Mohamad B. Sonbol, Jason S. Starr, Rachel A. Eiring, Timothy J. Hobday, Thorvardur R. Halfdanarson
Publikováno v:
Journal of Neuroendocrinology.
Autor:
Nicola Fazio, Lorenzo Gervaso, Thorvardur R Halfdanarson, Mohamad Sonbol, Rachel A Eiring, Sara Pusceddu, Natalie Prinzi, Benedetta Lombardi Stocchetti, Simona Grozinsky-Glasberg, David J Gross, Thomas Walter, Patrick Robelin, Catherine Lombard-Bohas, Samuele Frassoni, Vincenzo Bagnardi, Lorenzo Antonuzzo, Clotilde Sparano, Sara Massironi, Fabio Gelsomino, Alberto Bongiovanni, Nicoletta Ranallo, Salvatore Tafuto, Maura Rossi, Mauro Cives, Ibrahim Rasul Kakil, Hytam Hamid, Alessandra Chirco, Michela Squadroni, Anna La Salvia, Jorge Hernando, Johannes Hofland, Anna Koumarianou, Sabrina Boselli, Darina Tamayo, Cristina Mazzon, Manila Rubino, Francesca Spada
Publikováno v:
Endocrine-Related Cancer. 30
We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. No
Autor:
Timothy J. Hobday, Patrick W. McGarrah, Thorvardur R. Halfdanarson, Jennifer Gile, Rachel A. Eiring, Jason S. Starr, Mohamad Bassam Sonbol, Alex J. Liu
Publikováno v:
Pancreas. 50:500-505
Objectives Checkpoint inhibitors (CPIs) for low- and intermediate-grade neuroendocrine tumors (NETs) have been associated with limited efficacy; recent studies suggest CPIs may represent promising treatment for high-grade neuroendocrine neoplasms (NE
Autor:
A Tuba Kendi, Denise N. Gansen, Ayca Dundar, Brian J. Burkett, Jason R. Young, Cynthia M. Patton, Rachel A. Eiring, Geoffrey B. Johnson, Thorvardur R. Halfdanarson, Annie T. Packard
Publikováno v:
Radiology. 298:261-274
Lutetium 177 (177Lu) DOTA-0-Tyr3-Octreotate (DOTATATE) peptide receptor radionuclide therapy (PRRT) is an effective treatment for advanced gastroenteropancreatic neuroendocrine tumors. This review presents a clinical practice workflow that has been s
Autor:
Rachel A. Eiring, Thorvardur R. Halfdanarson, Lehar Khanna, Teresa Prond, Michael Camilleri, Mohamad Bassam Sonbol
Publikováno v:
Digestive diseases and sciences. 67(6)
Chronic diarrhea in patients with neuroendocrine tumors (NET) may be caused by bioactive products of NET, bile acid malabsorption (BAM), ileal resection (IR) or steatorrhea. To quantitate BA and fat malabsorption in NET with diarrhea. Part of evaluat
Autor:
Brian J, Burkett, Ayca, Dundar, Jason R, Young, Annie T, Packard, Geoffrey B, Johnson, Thorvardur R, Halfdanarson, Rachel A, Eiring, Denise N, Gansen, Cynthia M, Patton, A Tuba, Kendi
Publikováno v:
Radiology. 298(2)
Lutetium 177 (
Autor:
Jacob A. Jochum, Mina Samir Erian Hanna, Tanios Bekaii-Saab, Wen Wee Ma, Henry C. Pitot, Jessica L Mitchell, Rachel A. Eiring, Aminah Jatoi, Caleb J. Smith, Thorvardur R. Halfdanarson, Kathryn D. Cook, Zhaohui Jin
Publikováno v:
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. 21(2)
Background Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment for metastatic pancreas cancer. It is unclear, however, whether patients who had received irinotecan derive benefit. Methods Medical records of metastatic pancreas can
Autor:
Zhaohui Jin, Jacob A. Jochum, Henry C. Pitot, Harry H. Yoon, Aminah Jatoi, Daniel S. Childs, Rachel A. Eiring
Publikováno v:
Support Care Cancer
PURPOSE. Falls can occur in older cancer patients, but few studies have examined falls in an age-unspecified group of patients with locally advanced esophageal cancer. Because these patients are often administered neuropathy-inducing agents, are weak
Publikováno v:
Pancreas. 50:e45-e46
Autor:
Christopher E. Wee, Timothy J. Hobday, A Tuba Kendi, Rachel A. Eiring, Ayca Dundar, Annie T. Packard, Thorvardur R. Halfdanarson, Mohamed Badawy
Publikováno v:
Journal of Nuclear Medicine. 62:1320-1320
TO THE EDITOR: With great interest, we recently read Strosberg et al.’s publication regarding the risk of bowel obstruction in patients with mesenteric or peritoneal disease who receive peptide receptor radionuclide therapy (PRRT) ([1][1]). At the